0001209191-22-062643.txt : 20221223 0001209191-22-062643.hdr.sgml : 20221223 20221223170307 ACCESSION NUMBER: 0001209191-22-062643 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221101 FILED AS OF DATE: 20221223 DATE AS OF CHANGE: 20221223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Galante Joseph C CENTRAL INDEX KEY: 0001632384 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33637 FILM NUMBER: 221486001 MAIL ADDRESS: STREET 1: 111 TENTH AVENUE STREET 2: SUITE 200 CITY: NASHVILLE STATE: TN ZIP: 37203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001087294 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE, STATE: TN ZIP: 37203 BUSINESS PHONE: 615-255-0068 MAIL ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-01 0 0001087294 CUMBERLAND PHARMACEUTICALS INC CPIX 0001632384 Galante Joseph C 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203 1 0 0 0 Common Stock 2022-11-01 4 P 0 65 2.53 A 54506 D Common Stock 2022-11-02 4 P 0 65 2.54 A 54571 D Common Stock 2022-11-03 4 P 0 65 2.44 A 54636 D Common Stock 2022-11-04 4 P 0 65 2.42 A 54701 D Common Stock 2022-11-07 4 P 0 65 2.45 A 54766 D Common Stock 2022-11-08 4 P 0 65 2.42 A 54831 D Common Stock 2022-11-09 4 P 0 65 2.37 A 54896 D Common Stock 2022-11-10 4 P 0 65 2.37 A 54961 D Common Stock 2022-11-11 4 P 0 65 2.32 A 55026 D Common Stock 2022-11-14 4 P 0 65 2.32 A 55091 D Common Stock 2022-11-15 4 P 0 65 2.35 A 55156 D Common Stock 2022-11-16 4 P 0 65 2.31 A 55221 D Common Stock 2022-11-17 4 P 0 65 2.29 A 55286 D Common Stock 2022-11-18 4 P 0 65 2.27 A 55351 D Common Stock 2022-11-21 4 P 0 65 2.38 A 55416 D Common Stock 2022-11-22 4 P 0 65 2.37 A 55481 D Common Stock 2022-11-23 4 P 0 65 2.29 A 55546 D Common Stock 2022-11-25 4 P 0 65 2.31 A 55611 D Common Stock 2022-11-28 4 P 0 65 2.37 A 55676 D Common Stock 2022-11-29 4 P 0 65 2.34 A 55741 D Common Stock 2022-11-30 4 P 0 65 2.32 A 55806 D The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Joseph C. Galante by /s/ John Hamm as attorney-in-fact 2022-12-23